By
Liz Highleyman
Published: March 29, 2015, 8:06 p.m.·
Tags:
Drug-susceptible TB,
Treatment
A combination regimen containing high-dose rifampin (also known as rifampicin) was associated with faster tuberculosis bacteria culture conversion in people with drug-sensitive TB, but moxifloxacin and the experimental drug SQ109 showed no benefit compared to standard therapy, according to results from a study presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Read More →
By
Liz Highleyman
Published: Aug. 31, 2012, 6:29 a.m.·
Tags:
None
The promising experimental tuberculosis (TB) drug delamanid does not interact with the widely used antiretrovirals tenofovir (Viread) and lopinavir/ritonavir (Kaletra) in ways likely to cause clinical problems, researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.
Read More →